Stocks
Eisai Co., Ltd.ESALY
OTCHealthcareBiotechnology$61.51-2.11%
A Japanese pharmaceutical company focused on neurology and oncology, Eisai is best known for developing treatments like the Alzheimer's drug Leqembi in partnership with Biogen. Investors monitor its pipeline for breakthroughs in neurodegenerative diseases and cancer therapies. The company maintains a strong presence in Japan and the U.S., with growing interest in its CNS and oncology portfolios.
Market Cap: $17.6B52W Range: $36.88 – $73.90
Congressional Interest in Eisai Co., Ltd. (ESALY)
1 member of Congress has disclosed 2 trades in Eisai Co., Ltd. (ESALY), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
0
Sells
2
Who in Congress Is Trading ESALY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-01-30 | Daniel Goldman | sell | $1K – $15K |
| 2023-01-13 | Daniel Goldman | sell | $1K – $15K |